By Michael King
In August, we expected a strong finish to the year for the biotech sector. Obviously, the Sept. 11 attacks have significantly altered investors’ attitudes about the market and economy. Most recently, many have remained wary as fears of a silent, stealthier weapon, against which we have little defense, have spread across the country.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
